Friday, November 17, 2017

Amgen Ventures Backs Syapse In $30M Precision Oncology Funding

Amgen Ventures, the venture investment arm of Thousand Oaks-based Amgen, is one of the new investors in precision oncology and medicine startup Syapse. Syapse said this week that it raised $30M in a Series D funding round, which came from Ascension Ventures, GE Ventures, Intermountain Healthcare Innovation Fund, Safeguard Scientifics, and Social Capital, plus new investors Amgen Ventures, Medidata Solutions, Merck Global Health Innovation Fund, and Roche Venture Fund. Syapse is baesd in Palo Alto, California, and develops precision oncology software which allows oncologists to view treatments and outcomes for patients of other oncologists across the country, to help improve their own treatment decisions. More information »

---